ArticleBiomaterials2017
Vascular smooth muscle cells derived from inbred swine induced pluripotent stem cells for vascular tissue engineering.
Article in Biomaterials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Vascular endothelial cells derived from transgene-free pig induced pluripotent stem cells for vascular tissue engineering.Acta biomaterialia · 2025Article
- Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency.Cell stem cell · 2025Article
- Engineering considerations of iPSC-based personalized medicine.Biomaterials research · 2023Review
- Small-Caliber Vascular Grafts Engineered from Decellularized Leaves and Cross-Linked Gelatin.Tissue engineering. Part A · 2023Article
- 3D bioprinting of an implantable xeno-free vascularized human skin graft.Bioengineering & translational medicine · 2023Article
- Clinical Application for Tissue Engineering Focused on Materials.Biomedicines · 2022Review
- Article
- Epigallocatechin gallate facilitates extracellular elastin fiber formation in induced pluripotent stem cell derived vascular smooth muscle cells for tissue engineering.Journal of molecular and cellular cardiology · 2022Article
- Human iPS Cell-derived Tissue Engineered Vascular Graft: Recent Advances and Future Directions.Stem cell reviews and reports · 2021Review
- Xenogeneic-free generation of vascular smooth muscle cells from human induced pluripotent stem cells for vascular tissue engineering.Acta biomaterialia · 2021Article
- Efficient Differentiation of Human Induced Pluripotent Stem Cells into Endothelial Cells under Xenogeneic-free Conditions for Vascular Tissue Engineering.Acta biomaterialia · 2021Article
- The use of induced pluripotent stem cells in domestic animals: a narrative review.BMC veterinary research · 2020Review
- Article
- Tethering transforming growth factor β1 to soft hydrogels guides vascular smooth muscle commitment from human mesenchymal stem cells.Acta biomaterialia · 2020Article
- Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs.Cell stem cell · 2020Article
- Induced pluripotent stem cell-derived smooth muscle cells increase angiogenesis and accelerate diabetic wound healing.Regenerative medicine · 2020Article
- Modular design of a tissue engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes.Acta biomaterialia · 2020Article
- Induced pluripotent stem cell-derived vascular smooth muscle cells.Vascular biology (Bristol, England) · 2020Review
- Rapid fabrication of reinforced and cell-laden vascular grafts structurally inspired by human coronary arteries.Nature communications · 2019Article
- Modeling elastin-associated vasculopathy with patient induced pluripotent stem cells and tissue engineering.Cellular and molecular life sciences : CMLS · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 2 countries.
Funding
Abstract
Development of autologous tissue-engineered vascular constructs using vascular smooth muscle cells (VSMCs) derived from human induced pluripotent stem cells (iPSCs) holds great potential in treating patients with vascular disease. However, preclinical, large animal iPSC-based cellular and tissue models are required to evaluate safety and efficacy prior to clinical application. Herein, swine iPSC (siPSC) lines were established by introducing doxycycline-inducible reprogramming factors into fetal fibroblasts from a line of inbred Massachusetts General Hospital miniature swine that accept tissue and organ transplants without immunosuppression within the line. Highly enriched, functional VSMCs were derived from siPSCs based on addition of ascorbic acid and inactivation of reprogramming factor via doxycycline withdrawal. Moreover, siPSC-VSMCs seeded onto biodegradable polyglycolic acid (PGA) scaffolds readily formed vascular tissues, which were implanted subcutaneously into immunodeficient mice and showed further maturation revealed by expression of the mature VSMC marker, smooth muscle myosin heavy chain. Finally, using a robust cellular self-assembly approach, we developed 3D scaffold-free tissue rings from siPSC-VSMCs that showed comparable mechanical properties and contractile function to those developed from swine primary VSMCs. These engineered vascular constructs, prepared from doxycycline-inducible inbred siPSCs, offer new opportunities for preclinical investigation of autologous human iPSC-based vascular tissues for patient treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.